anti-CD20/γδT cell receptor T cell engager GADLEN (Shattuck Labs)

N/A

Report date: 2025/01/26 18:22:12

Base Information

Drug Nameanti-CD20/γδT cell receptor T cell engager GADLEN (Shattuck Labs)
Drug Alias Nameanti-TCR/anti-CD20 bispecific T-cell engager GALDEN (Shattuck Labs Inc)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsT-cell receptor modulators
TargetsB-lymphocyte antigen CD20T-cell receptor
Therapy Area/IndicationsAutoimmune DiseasesLymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShattuck Labs Inc
China Registration ClassN/A

Develop Information

Active CompaniesShattuck Labs Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLymphoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A